Welcome to the e-CCO Library Archive!

Filter:
P358. Tetrahydrocannabinol (THC) induces clinical and biochemical improvement with a steroid sparing effect in active inflammatory bowel disease
Authors:

T. Naftali1, L. Barlev2, G. Gabay1, Y. Chowers3, I. Dotan4, A. Stein1, M. Bronstein1, F.M. Konikoff1, 1Meir General Hospital, Gastroenterology, Kfar Saba, Israel, 2Tel aviv University, pschology, Tel Aviv, Israel, 3Rambam Health care campus, Gastroenterology, Haifa, Israel, 4Tel Aviv Sorasky Medical center, Gastroenterology, Tel Aviv, Israel

P358

Long term efficacy of granulocyte-monocyte-apheresis in ulcerative colitis elderly patients. The Italian Registry of Therapeutic Apheresis.

Authors:

R. Sacco*1, V. D'Ovidio2, A. Romano3, M. Bertini4, M. Bertoni4, G. Federici1, S. Metrangolo3, E. Tumino1, P. Giuseppe1, G. Bresci1, V. Mismas1, P. Vernia2

1Pisa University Hospital, Gastroenterology, Pisa, Italy, 2Policlinico Umberto I, Gastroenterology, Rome, Italy, 3Pisa University Hospital, Gastroenterology, Pisa, Italy, 4Pisa University Hospital, Gastroenterology , Pisa, Italy

P359.

Risk factors for pouchitis after laparoscopic ileal-pouch-anal anastomosis in patients with ulcerative colitis

Authors:

R. Gonzalez1, L. Pereyra1, M. Omodeo1, E. Gómez1, J.M. Mella1, G.N. Panigadi1, C. Fischer1, B. Vizcaino1, A. Hadad1, M. Bun2, A. Canelas2, N. Rotholtz2, D.G. Cimmino1, S.C. Pedreira1, L.A. Boerr1, 1Hospital Alemán, Gastroenterology, Buenos Aires, Argentina, 2Hospital Alemán, Colorectal Surgery Section, Buenos Aires, Argentina

P359. Quality of life in ulcerative colitis patients treated medically versus patients undergoing surgery
P359. Role of the CYLD protease gene in Crohn's disease, independent from its neighbouring gene CARD15
P359. Systematic assessment of the frequency and risk factors of anti-TNF drug switch in the Swiss IBD Cohort
Authors:

P. Hiroz1, N. Fournier2, E. Safroneeva3, S. Vavricka4, A. Schoepfer1, 1University Hospital Lausanne / CHUV, Gastroenterology and Hepatology, Lausanne, Switzerland, 2University of Lausanne, Institute of Social and Preventive Medicine, Lausanne, Switzerland, 3University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 4University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

P359

Meta-analysis of the effects of anti- tumour necrosis factor alpha therapies on pregnancy outcomes in women with Inflammatory Bowel Disease

Authors:

Z. Shihab1, N. Yeomans1, P. De Cruz*1, 2, 3

1Austin Health, Office of Research, Melbourne, Australia, 2Austin Health, Department of Gastroenterology, Melbourne, Australia, 3St Vincents Health, Department of Gastroenterology, Melbourne, Australia

P360.

Risk factors for complications after laparoscopic ileal-pouch-anal anastomosis in patients with ulcerative colitis

Authors:

R. Gonzalez1, L. Pereyra1, M. Omodeo1, E. Gómez1, J.M. Mella1, G.N. Panigadi1, C. Fischer1, B. Vizcaino1, A. Hadad1, M. Bun2, A. Canelas2, N. Rotholtz2, D.G. Cimmino1, S.C. Pedreira1, L.A. Boerr1, 1Hospital Alemán, Gastroenterology, Buenos Aires, Argentina, 2Hospital Alemán, Colorectal Surgery Section, Buenos Aires, Argentina

P360. Candidate genes for azathioprine's efficacy or toxicity in inflammatory bowel disease patients using a exome-wide genotyping analysis
P360. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease: A single cohort study
P360. Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial
Authors:

A. Dignass1, B. Bokemeyer2, M. Mross3, M. Oudkerk Pool4, 1Agaplesion Markus Hospital, Frankfurt, Germany, 2Gastroenterologische Gemeinschaftspraxis, Minden, Germany, 3Internistische Praxis, Berlin, Germany, 4Gelre Ziekenhuizen, Apeldoorn, Netherlands

P360

Adalimumab in perianal Crohn's disease treatment: Experience of a tertiary center

Authors:

D. Carvalho*1, C. Bernardes1, P. Russo1, J. Saiote1, S. Nunes2, J. Ramos1

1Hospital Santo António dos Capuchos, Gastroenterology, Lisboa, Portugal, 2Hospital Santo António dos Capuchos, General Surgery, Lisboa, Portugal

P361.

Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy

Authors:

S. Miehlke1, J.B. Hansen2, A. Madisch3, F. Schwarz4, E. Kuhlisch5, A. Morgner6, P.S. Teglbjaerg7, M. Vieth8, D. Aust9, O.K. Bonderup10, 1Magen-Darm-Zentrum, Facharztzentrum Eppendorf, Hamburg, Germany, 2Aalborg Hospital, Department of Gastroenterology, Aalborg, Denmark, 3Siloah Hospital, Medical Department I, Hannover, Germany, 4University Hospital, Medical Department III, Dresden, Germany, 5Technical University, Institute for Medical Informatics and Biometry, Dresden, Germany, 6Lanserhof Hamburg GmbH, LANS MEDICUM, Hamburg, Germany, 7Aalborg Hospital, Institute of Pathology, Aalborg, Denmark, 8Klinikum Bayreuth, Institute for Pathology, Bayreuth, Germany, 9University Hospital, Institute for Pathology, Dresden, Germany, 10Regional Hospital Silkeborg, Diagnostic Center, Section of Gastroenterology, Silkeborg, Denmark

P361. Adalimumab in the treatment of perianal Crohn's disease: Long‑term results in a single tertiary center
P361. Sustained clinical response and remission achieved in moderately severe ulcerative colitis patients by local application of the TLR-9 agonist DIMS0150
Authors:

T. Knittel1, R. Befrits2, R. Löfberg3, Å. Öst4, P. von Stein1, O. von Stein1, 1InDex Pharmaceuticals, Stockholm, Sweden, 2Dept. of Gastroenterology, Karolinska, Stcokholm, Sweden, 3IBD unit Sophiahemmet and the Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Aleris-Medilab AB, Stockholm, Sweden

P361. Whole-transcript human gene expression pathway analysis in Crohn's disease
P361

Effects of azathioprine on outcome of pregnancy in Inflammatory Bowel Disease patients: A prospective study

Authors:

L. Kecili*, N. Bounab, N. Kaddache, K. Layaida, T. Boucekkine, N. Debzi, S. Berkane

CHU Mustapha, Gastroenterology, Alger, Algeria

P362.

Retrospective comparison of the efficacy of anti-TNF agents in isolation or combined with azathioprine in prevention of early postoperative endoscopic recurrence in Crohn's disease from the MULTIPER database

Authors:

Y. Suzuki1, P.G. Kotze2, A. Spinelli3,4, R. Saad-Hossne5, A. Yamada1, M. Sacchi3, F. Teixeira6, I. Albuquerque7, I. Barcelos2, R. Silva2, L. Kotze8, M. Olandoski9, S. Danese10, T. Yamamoto11, 1Toho University – Sakura Medical Center, Internal Medicine, Chiba, Japan, 2Cajuru University Hospital – Catholic University of Parana, Colorectal Surgery Unit, Curitiba, Brazil, 3Humanitas Research Hospital, Medical Biotechnologies and Translational Medicine, Milano, Italy, 4Humanitas Research Hospital, IBD Surgery Unit, Milano, Italy, 5São Paulo State University, Digestive Surgery Department, Botucatu, Brazil, 6Gastrosaude, Colorectal Surgery, Marilia, Brazil, 7Heliopolis Hospital, IBD unit, São Paulo, Brazil, 8Cajuru University Hospital – Catholic University of Parana, Gastroenterology, Curitiba, Brazil, 9Catholic University of Paraná, Statistics, Curitiba, Brazil, 10Humanitas Research Hospital, IBD Unit – Gastroenterology, Milano, Italy, 11Yokkaichi Social Insurance Hospital, IBD Unit, Yokkaichi, Japan

P362. Autologous haematopoietic stem cell transplantation without CD34+ cell selection for refractory Crohn's disease: The Milan experience after 5 years
P362. Pharmacogenetics study of TPMT and ITPA genes in patients with inflammatory bowel disease treated with azathioprine detects relation between ITPase deficiency and clinical response